Previous Close | 19.30 |
Open | 19.30 |
Bid | 19.60 |
Ask | 20.55 |
Strike | 47.50 |
Expire Date | 2024-06-21 |
Day's Range | 19.30 - 19.30 |
Contract Range | N/A |
Volume | |
Open Interest | 5 |
Lilly (LLY) delivered earnings and revenue surprises of 1.98% and 0.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
COPENHAGEN, Denmark, April 29, 2024--Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This FDA action converts the September 2021 accelerated approval of TIVDAK to a full approval. TIVDAK is the first anti
NEW YORK & COPENHAGEN, Denmark, April 29, 2024--Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.